Etern Pharma Raises ￥100 million in Series A, To Develop First-in-class Anticancer Drugs for Difficult Drug Targets

According to VCBeat, Shanghai Etern Pharmaceutical Technology Co., Ltd. ("Etern Pharma") recently announced the completion of its Series A financing of nearly 100 million yuan, co-led by Apricot Capital and TF Capital, with participation from existing investor BOHE Angel Fund.

Proceeds of this round will be used for the pre-clinical development and early clinical trials of pipelines.

Etern Pharma completed an angel round financing of tens of millions yuan led by BOHE Angel Fund with participation from Nuokaishenkang Fund.

Etern Pharma is a research and development company of small-molecule drugs, focusing on 'undruggable' cancer targets. Based on the mechanisms of structural biology and molecular biology, the company provides innovative solutions for tumor therapy by accurately targeting 'undruggable' targets through a variety of targeting mechanisms.

'Undruggable' targets refer to those proteins that are difficult to target with small molecules. Although these targets play an important role in the occurrence and development of diseases, effective small-molecule drugs have not been developed due to the protein structure or regulatory mechanism.

Etern Pharma has developed solutions for these targets, such as the development of allosteric inhibitors, inhibiting protein-protein interactions, and promoting protein degradation. The team has established technical systems of structural biology, computer-aided drug design (CADD), DNA-encoded chemical library and molecular building block, forming an efficient model from discovery to optimization.

Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.

TF Capital focuses on investment in the life sciences industry, including biotechnology, therapeutics & pharmaceuticals, drug delivery, medical device & instruments, and medical service, primarily investing in early-stage companies with high potential.